Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2018-06-22 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于中信资本股权投资（天津）股份有限公司终止要约收购公司股份的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Harbin Pharmaceutical Group Co., Ltd. regarding the termination of a planned tender offer and capital increase agreement involving CITIC Capital Equity Investment (Tianjin) Co., Ltd. It details the background of the proposed transaction, the approvals obtained and pending, and the reasons for termination due to regulatory and policy changes. The document is a formal public disclosure about the cessation of a financing and acquisition-related transaction, not a full financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about the termination of a capital increase and tender offer process. This fits the category of a Capital/Financing Update (CAP) as it relates to changes in financing activities and capital structure plans that have been terminated.
2018-06-22 Chinese
收到上海证券交易所关于哈药集团有限公司终止增资扩股事项事项的监管工作函的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Harbin Pharmaceutical Group Co., Ltd. regarding a regulatory letter received from the Shanghai Stock Exchange about the termination of a capital increase and share expansion matter. It discusses regulatory compliance, disclosure obligations, and the company's response to the regulatory letter. The document is short (1263 characters) and primarily serves as a regulatory announcement rather than a detailed financial report or other specific filing. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-06-21 Chinese
关于哈尔滨市国资委终止本次哈药集团增资扩股有关事宜的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by 哈药集团股份有限公司 regarding the termination of a capital increase and share expansion plan by its controlling shareholder 哈药集团有限公司. It references regulatory approvals, government notices, and changes in policy affecting the transaction. The document is short (1130 characters) and primarily informs about the termination of a financing-related event and the cessation of a takeover offer. It does not contain financial statements, detailed financial data, or management discussion. It is an announcement about capital and financing activities rather than a full report or regulatory filing. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-06-21 Chinese
关于哈药集团有限公司增资事宜的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding a capital increase (增资) involving the company's controlling shareholder and changes in shareholding structure. It discusses regulatory changes affecting the capital increase and the risk of termination of the transaction. The document length is only 1102 characters, which is quite short and does not contain detailed financial data or full report content. It is an update on a financing/capital structure event rather than a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2018-06-15 Chinese
关于参加投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement about the company's participation in an online investor collective reception day event. It mentions the date and time of the event and the participation of company directors and executives for Q&A with investors. There is no financial data, no detailed report, no voting results, no regulatory certification, or other detailed filings. The document is an announcement related to investor relations and communication, not a formal report or transcript. Given the short length (522 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2018-06-05 Chinese
关于认购GNC发行的可转换优先股事宜的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the progress of a subscription to convertible preferred shares issued by GNC. It includes details about the investment approval, board and shareholder meeting approvals, and pending regulatory filings. The document is relatively short (802 characters) and serves as a progress update on a financing transaction rather than a full financial report or detailed capital structure change. It does not contain financial statements or detailed analysis but rather informs about the status and approvals related to a capital investment. Therefore, it fits best under Capital/Financing Update (CAP).
2018-06-04 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.